Artificial kidneys are a cutting-edge technology that is being developed to replace natural kidneys and reduce or eliminate the need for dialysis. Those
BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 Cellectis , a clinical-stage biotechnology company. | May 11, 2023
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
More than a year after imposing a clinical hold on MaaT Pharma’s lead microbiome therapeutic in 2021, the US Food and Drug Administration (FDA) has given clearance for the French firm to begin a phase 3 trial in the US.